Please enable JavaScript to continue using this application.

Compare $IOVA vs $RYTM | Chartloom

Compare

$IOVA vs $RYTM

Iovance Biotherapeutics Inc · Rhythm Pharmaceuticals Inc

IOVA

Iovance Biotherapeutics Inc

RYTM

Rhythm Pharmaceuticals Inc

Compare $IOVA vs $RYTM

Comparing Iovance Biotherapeutics Inc and Rhythm Pharmaceuticals Inc

IOVAIovance Biotherapeutics Inc

RYTMRhythm Pharmaceuticals Inc

IOVAIovance Biotherapeutics Inc

Market cap

$6.53B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

12.69x

Rev growth (TTM)

34.5%

YTD performance

480.2%

52W performance

544.1%

FCF yield

-4.5%

RYTMRhythm Pharmaceuticals Inc

Market cap

$6.22B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

15.08x

Rev growth (TTM)

53.5%

YTD performance

-13.6%

52W performance

-9.4%

FCF yield

-1.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

IOVA

RYTM

Detailed metrics comparison

IOVA

Iovance Biotherapeutics Inc

RYTM

Rhythm Pharmaceuticals Inc

Market Cap

IOVA$6.53B

RYTM$6.22B

Enterprise Value

IOVA$6.42B

RYTM$6.26B

Price

IOVA$14.62

RYTM$90.78

P/E Ratio

IOVAN/A

RYTMN/A

P/S Ratio

IOVA20.09x

RYTM25.93x

EV/Sales

IOVA19.75x

RYTM26.10x

EV/EBITDA

IOVA0.00x

RYTM0.00x

P/B Ratio

IOVA8.75x

RYTM29.41x

P/FCF Ratio

IOVAN/A

RYTMN/A

EV/FCF

IOVA-21.65x

RYTM-58.90x

PEG Ratio

IOVAN/A

RYTMN/A

Forward P/E (NTM)

IOVAN/A

RYTMN/A

Forward P/S (NTM)

IOVA12.69x

RYTM15.08x

Revenue (TTM)

IOVA$325M

RYTM$240M

Revenue Growth (YoY)

IOVA34.5%

RYTM53.5%

Forward Rev Growth

IOVA39.2%

RYTM77.4%

Gross Margin (TTM)

IOVA48.4%

RYTM70.9%

Operating Margin (TTM)

IOVA0.0%

RYTM0.0%

EBITDA Margin (TTM)

IOVA-79.8%

RYTM-83.2%

Net Margin (TTM)

IOVA-89.1%

RYTM-87.6%

FCF Margin (TTM)

IOVA-91.2%

RYTM-44.3%

Net Income (TTM)

IOVA$-290M

RYTM$-210M

FCF (TTM)

IOVA$-296M

RYTM$-106M

EPS (TTM)

IOVA-$0.64

RYTM-$3.06

ROE (TTM)

IOVA-4051.0%

RYTM-8048.0%

ROA (TTM)

IOVA-3165.0%

RYTM-4400.0%

ROIC (TTM)

IOVA-4047.0%

RYTM-5656.0%

Cash

IOVA$111M

RYTM$66M

Debt

IOVA$0

RYTM$106M

Net Cash/Debt

IOVA$111M

RYTM$-40M

Current Ratio (TTM)

IOVA4.35x

RYTM3.45x

Quick Ratio (TTM)

IOVA3.74x

RYTM3.00x

Debt/Equity (TTM)

IOVA0.00x

RYTM0.49x

Debt/Assets (TTM)

IOVA0.0%

RYTM0.0%

Interest Coverage (TTM)

IOVAN/A

RYTMN/A

Net Debt/EBITDA (TTM)

IOVA0.00x

RYTM0.00x

Beta

IOVA0.76

RYTM2.13

52W Performance

IOVA544.1%

RYTM-9.4%

YTD Performance

IOVA480.2%

RYTM-13.6%

% from 52W High

IOVA-4.4%

RYTM-25.7%

% from 52W Low

IOVA730.7%

RYTM21.9%

Asset Turnover (TTM)

IOVA0.36x

RYTM0.51x

FCF Yield (TTM)

IOVA-4.5%

RYTM-1.7%

Earnings Yield (TTM)

IOVA-4.4%

RYTM-3.4%

Dividend Yield (TTM)

IOVAN/A

RYTMN/A

Rule of 40

IOVA-56.7

RYTM9.2

EV/GP/RG

IOVA0.68

RYTM0.49

Ticker research

View IOVA research View RYTM research

Metric	IOVA Iovance Biotherapeutics Inc	RYTM Rhythm Pharmaceuticals Inc
Market & Valuation
Market Cap	$6.53B	$6.22B
Enterprise Value	$6.42B	$6.26B
Price	$14.62	$90.78
P/E Ratio	N/A	N/A
P/S Ratio	20.09x	25.93x
EV/Sales	19.75x	26.10x
EV/EBITDA	0.00x	0.00x
P/B Ratio	8.75x	29.41x
P/FCF Ratio	N/A	N/A
EV/FCF	-21.65x	-58.90x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	12.69x	15.08x
Revenue & Growth
Revenue (TTM)	$325M	$240M
Revenue Growth (YoY)	34.5%	53.5%
Forward Rev Growth	39.2%	77.4%
Profitability
Gross Margin (TTM)	48.4%	70.9%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-79.8%	-83.2%
Net Margin (TTM)	-89.1%	-87.6%
FCF Margin (TTM)	-91.2%	-44.3%
Net Income (TTM)	$-290M	$-210M
FCF (TTM)	$-296M	$-106M
EPS (TTM)	-$0.64	-$3.06
ROE (TTM)	-4051.0%	-8048.0%
ROA (TTM)	-3165.0%	-4400.0%
ROIC (TTM)	-4047.0%	-5656.0%
Financial Health
Cash	$111M	$66M
Debt	$0	$106M
Net Cash/Debt	$111M	$-40M
Current Ratio (TTM)	4.35x	3.45x
Quick Ratio (TTM)	3.74x	3.00x
Debt/Equity (TTM)	0.00x	0.49x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.76	2.13
52W Performance	544.1%	-9.4%
YTD Performance	480.2%	-13.6%
% from 52W High	-4.4%	-25.7%
% from 52W Low	730.7%	21.9%
Efficiency & Yields
Asset Turnover (TTM)	0.36x	0.51x
FCF Yield (TTM)	-4.5%	-1.7%
Earnings Yield (TTM)	-4.4%	-3.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-56.7	9.2
EV/GP/RG	0.68	0.49
Ticker research	View IOVA research	View RYTM research

Valuation

P/S Ratio

IOVA

20.09x

RYTM

25.93x

EV/FCF

RYTM

-58.90x

IOVA

-21.65x

Growth & revenue

Revenue Growth TTM

RYTM

53.5%

IOVA

34.5%

Forward Revenue Growth

RYTM

77.4%

IOVA

39.2%

Profitability & performance

Gross Margin

RYTM

70.9%

IOVA

48.4%

ROE

IOVA

-4051.0%

RYTM

-8048.0%

FCF Yield %

RYTM

-1.7%

IOVA

-4.5%

52-Week Performance

IOVA

544.1%

RYTM

-9.4%

Detailed metrics comparison

IOVA

Iovance Biotherapeutics Inc

RYTM

Rhythm Pharmaceuticals Inc

Market Cap

IOVA$6.53B

RYTM$6.22B

Enterprise Value

IOVA$6.42B

RYTM$6.26B

Price

IOVA$14.62

RYTM$90.78

P/E Ratio

IOVAN/A

RYTMN/A

P/S Ratio

IOVA20.09x

RYTM25.93x

EV/Sales

IOVA19.75x

RYTM26.10x

EV/EBITDA

IOVA0.00x

RYTM0.00x

P/B Ratio

IOVA8.75x

RYTM29.41x

P/FCF Ratio

IOVAN/A

RYTMN/A

EV/FCF

IOVA-21.65x

RYTM-58.90x

PEG Ratio

IOVAN/A

RYTMN/A

Forward P/E (NTM)

IOVAN/A

RYTMN/A

Forward P/S (NTM)

IOVA12.69x

RYTM15.08x

Revenue (TTM)

IOVA$325M

RYTM$240M

Revenue Growth (YoY)

IOVA34.5%

RYTM53.5%

Forward Rev Growth

IOVA39.2%

RYTM77.4%

Gross Margin (TTM)

IOVA48.4%

RYTM70.9%

Operating Margin (TTM)

IOVA0.0%

RYTM0.0%

EBITDA Margin (TTM)

IOVA-79.8%

RYTM-83.2%

Net Margin (TTM)

IOVA-89.1%

RYTM-87.6%

FCF Margin (TTM)

IOVA-91.2%

RYTM-44.3%

Net Income (TTM)

IOVA$-290M

RYTM$-210M

FCF (TTM)

IOVA$-296M

RYTM$-106M

EPS (TTM)

IOVA-$0.64

RYTM-$3.06

ROE (TTM)

IOVA-4051.0%

RYTM-8048.0%

ROA (TTM)

IOVA-3165.0%

RYTM-4400.0%

ROIC (TTM)

IOVA-4047.0%

RYTM-5656.0%

Cash

IOVA$111M

RYTM$66M

Debt

IOVA$0

RYTM$106M

Net Cash/Debt

IOVA$111M

RYTM$-40M

Current Ratio (TTM)

IOVA4.35x

RYTM3.45x

Quick Ratio (TTM)

IOVA3.74x

RYTM3.00x

Debt/Equity (TTM)

IOVA0.00x

RYTM0.49x

Debt/Assets (TTM)

IOVA0.0%

RYTM0.0%

Interest Coverage (TTM)

IOVAN/A

RYTMN/A

Net Debt/EBITDA (TTM)

IOVA0.00x

RYTM0.00x

Beta

IOVA0.76

RYTM2.13

52W Performance

IOVA544.1%

RYTM-9.4%

YTD Performance

IOVA480.2%

RYTM-13.6%

% from 52W High

IOVA-4.4%

RYTM-25.7%

% from 52W Low

IOVA730.7%

RYTM21.9%

Asset Turnover (TTM)

IOVA0.36x

RYTM0.51x

FCF Yield (TTM)

IOVA-4.5%

RYTM-1.7%

Earnings Yield (TTM)

IOVA-4.4%

RYTM-3.4%

Dividend Yield (TTM)

IOVAN/A

RYTMN/A

Rule of 40

IOVA-56.7

RYTM9.2

EV/GP/RG

IOVA0.68

RYTM0.49

Ticker research

View IOVA research View RYTM research

Metric	IOVA Iovance Biotherapeutics Inc	RYTM Rhythm Pharmaceuticals Inc
Market & Valuation
Market Cap	$6.53B	$6.22B
Enterprise Value	$6.42B	$6.26B
Price	$14.62	$90.78
P/E Ratio	N/A	N/A
P/S Ratio	20.09x	25.93x
EV/Sales	19.75x	26.10x
EV/EBITDA	0.00x	0.00x
P/B Ratio	8.75x	29.41x
P/FCF Ratio	N/A	N/A
EV/FCF	-21.65x	-58.90x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	12.69x	15.08x
Revenue & Growth
Revenue (TTM)	$325M	$240M
Revenue Growth (YoY)	34.5%	53.5%
Forward Rev Growth	39.2%	77.4%
Profitability
Gross Margin (TTM)	48.4%	70.9%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-79.8%	-83.2%
Net Margin (TTM)	-89.1%	-87.6%
FCF Margin (TTM)	-91.2%	-44.3%
Net Income (TTM)	$-290M	$-210M
FCF (TTM)	$-296M	$-106M
EPS (TTM)	-$0.64	-$3.06
ROE (TTM)	-4051.0%	-8048.0%
ROA (TTM)	-3165.0%	-4400.0%
ROIC (TTM)	-4047.0%	-5656.0%
Financial Health
Cash	$111M	$66M
Debt	$0	$106M
Net Cash/Debt	$111M	$-40M
Current Ratio (TTM)	4.35x	3.45x
Quick Ratio (TTM)	3.74x	3.00x
Debt/Equity (TTM)	0.00x	0.49x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.76	2.13
52W Performance	544.1%	-9.4%
YTD Performance	480.2%	-13.6%
% from 52W High	-4.4%	-25.7%
% from 52W Low	730.7%	21.9%
Efficiency & Yields
Asset Turnover (TTM)	0.36x	0.51x
FCF Yield (TTM)	-4.5%	-1.7%
Earnings Yield (TTM)	-4.4%	-3.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-56.7	9.2
EV/GP/RG	0.68	0.49
Ticker research	View IOVA research	View RYTM research